Recent studies have further elucidated that RRM2 contributes to resistance against docetaxel chemotherapy by stabilizing ANXA1 and activating the PI3K/AKT signaling pathway, thereby enhancing tumor cell survival under chemotherapeutic stress (48). Here, ANXA1 is linked to neoplasm.